Aktuelle Dermatologie 2022; 48(04): 162-169
DOI: 10.1055/a-1774-9766

Kutane Sarkome – nicht alle sind wirklich selten, die meisten „low risk“

Cutaneous Sarcomas – Not All Are Really Rare, Most Are “Low Risk”
Thomas Vogt
Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum der Universität des Saarlandes
› Author Affiliations


Die biologische und morphologische Vielfalt der Weichteilmalignome, der Sarkome, ist enorm.

Diese Übersicht fokussiert deshalb auf die 5 am häufigsten vorkommenden Weichteilmalignome. Betrachtet werden soll dabei, was der Kliniker wissen muss, was neu ist und welche Fallstricke es gibt. Ziel dieses Artikels ist es dabei, eine Übersicht zu geben sowie die Konzeptbildung darüber, womit man es im Wesentlichen zu tun hat.


The biological and morphological diversity of soft tissue malignancies, sarcomas, is enormous. This review therefore focuses on the five most common soft tissue malignancies. Consideration will be given to what the clinician needs to know, what is new, and what are the pitfalls. The goal of this article is to provide an overview and conceptualization.

Publication History

Article published online:
14 April 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Literatur

  • 1 Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives. Pathologica 2021; 113: 70-84
  • 2 Stanisz H, Pföhler C, Anagnostakos K. et al. Metastatic chondrosarcoma – current aspects of a rare event in dermatopathology. J Cutan Pathol 2012; 39: 467-470
  • 3 Salamanca J, Dhimes P, Pinedo F. et al. Extraskeletal cutaneous chondroblastic osteosarcoma: a case report. J Cutan Pathol 2008; 35: 231-235
  • 4 Stojsic Z, Brasanac D, Stojanovic M. et al. Cutaneous composite hemangioendothelioma: case report and review of published reports. Ann Saudi Med 2014; 34: 182-188
  • 5 Müller CS, Pföhler C, Kohn D. et al. Huge undifferentiated fibroblastic sarcoma of the foot and lower leg: impact of diagnostic delay and discussion of an entity. BMJ Case Rep 2013; 2013: bcr2013200192
  • 6 Rouhani P, Fletcher CD, Devesa SS. et al. Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12,114 cases. Cancer 2008; 113: 616-627
  • 7 Casali PG, Abecassis N, Aro HT. et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29: iv51-iv67
  • 8 Lebbe C, Garbe C, Stratigos AJ. et al. Diagnosis and treatment of Kaposiʼs sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). Eur J Cancer 2019; 114: 117-127
  • 9 Sakamoto A, Oda Y, Itakura E. et al. Immunoexpression of ultraviolet photoproducts and p53 mutation analysis in atypical fibroxanthoma and superficial malignant fibrous histiocytoma. Mod Pathol 2001; 14: 581-588
  • 10 Bitel A, Schonlebe J, Kronert C. et al. Atypical fibroxanthoma: An analysis of 105 tumors. Dermatol Ther 2020; 33: e13962
  • 11 Phelan PS, Rosman IS, Council ML. Atypical Fibroxanthoma: The Washington University Experience. Dermatol Surg 2019; 45: 1450-1458
  • 12 Rosenfeld D, Alam M, Van Tine B. et al. Atypical fibroxanthoma: A malignant tumor of the skin and soft tissue. J Am Acad Dermatol 2020; 83: e429-e430
  • 13 Miller K, Goodlad JR, Brenn T. Pleomorphic dermal sarcoma: adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma. Am J Surg Pathol 2012; 36: 1317-1326
  • 14 Helbig D, Ziemer M, Dippel E. et al. S1-guideline atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS). J Dtsch Dermatol Ges 2022; 20: 235-243
  • 15 Müller CS, Jungmann J, Pföhler C. et al. Report on immediate irradiation of a rapidly growing sarcoma of the scalp prior to wound closure. J Dtsch Dermatol Ges 2016; 14: 539-542
  • 16 Müller CS, Schiekofer C, Korner R. et al. Improved patient-centered care with effective use of Integra(R) in dermatologic reconstructive surgery. J Dtsch Dermatol Ges 2013; 11: 537-548
  • 17 Ugurel S, Kortmann RD, Mohr P. et al. S1 guidelines for dermatofibrosarcoma protuberans (DFSP) – update 2018. J Dtsch Dermatol Ges 2019; 17: 663-668
  • 18 Noujaim J, Thway K, Fisher C. et al. Dermatofibrosarcoma protuberans: from translocation to targeted therapy. Cancer Biol Med 2015; 12: 375-384
  • 19 Navarrete-Dechent C, Mori S, Barker CA. et al. Imatinib Treatment for Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans: A Systematic Review. JAMA Dermatol 2019; 155: 361-369
  • 20 Ugurel S, Becker JC. Imatinib in Dermatofibrosarcoma: Targeted Therapy or Immunotherapy?. J Invest Dermatol 2017; 137: 277-279
  • 21 Liang CA, Jambusaria-Pahlajani A, Karia PS. et al. A systematic review of outcome data for dermatofibrosarcoma protuberans with and without fibrosarcomatous change. J Am Acad Dermatol 2014; 71: 781-786
  • 22 Massi D, Franchi A, Alos L. et al. Primary cutaneous leiomyosarcoma: clinicopathological analysis of 36 cases. Histopathology 2010; 56: 251-262
  • 23 Cazzato G, Sergi MC, Sablone S. et al. Advanced Cutaneous Leiomyosarcoma of the Forearm. Dermatopathology (Basel) 2021; 8: 40-44
  • 24 Chalfant V, Schriber T, Sabri A. et al. Primary Cutaneous Leiomyosarcoma of the Lower Extremity: A Case Report and Literature Review. Cureus 2021; 13: e14282
  • 25 Soares Queiros C, Filipe P, Soares de Almeida L. Cutaneous leiomyosarcoma: a 20-year retrospective study and review of the literature. An Bras Dermatol 2021; 96: 278-283
  • 26 Vogt T, Müller CSL, Melchior P. et al. S1-Guideline Cutaneous Angiosarcomas – Update 2021. J Dtsch Dermatol Ges 2021; 19: 1801-1812
  • 27 Machado I, Giner F, Lavernia J. et al. Angiosarcomas: histology, immunohistochemistry and molecular insights with implications for differential diagnosis. Histol Histopathol 2021; 36: 3-18
  • 28 Shustef E, Kazlouskaya V, Prieto VG. et al. Cutaneous angiosarcoma: a current update. J Clin Pathol 2017; 70: 917-925
  • 29 Milam EC, Rangel LK, Pomeranz MK. Dermatologic sequelae of breast cancer: From disease, surgery, and radiation. Int J Dermatol 2021; 60: 394-406
  • 30 Khanna L, Prasad SR, Yedururi S. et al. Second Malignancies after Radiation Therapy: Update on Pathogenesis and Cross-sectional Imaging Findings. Radiographics 2021; 41: 876-894
  • 31 Fineberg S, Rosen PP. Cutaneous angiosarcoma and atypical vascular lesions of the skin and breast after radiation therapy for breast carcinoma. Am J Clin Pathol 1994; 102: 757-763
  • 32 Guadagnolo BA, Zagars GK, Araujo D. et al. Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp. Head Neck 2011; 33: 661-667
  • 33 Guida M, Campana LG, Curatolo P. et al. Local treatment with electrochemotherapy of superficial angiosarcomas: Efficacy and safety results from a multi-institutional retrospective study. J Surg Oncol 2016; 114: 246-253
  • 34 Zhou G, Mei Z. Electrochemotherapy for advanced cutaneous angiosarcoma: A european register-based cohort study from the international network for sharing practices of electrochemotherapy (InspECT) – An invited commentary. Int J Surg 2019; 72: 232-233
  • 35 Ihara H, Kaji T, Katsui K. et al. Single institutional experience of radiation therapy for angiosarcoma of the scalp without cervical lymph node metastases: Impact of concurrent chemoradiation with maintenance chemotherapy using taxanes on patient prognosis. Mol Clin Oncol 2019; 11: 498-504
  • 36 Lebellec L, Defachelles AS, Cren PY. et al. Maintenance therapy and drug holiday in sarcoma patients: systematic review. Acta Oncol 2020; 59: 1084-1090
  • 37 Ishida Y, Otsuka A, Kabashima K. Cutaneous angiosarcoma: update on biology and latest treatment. Curr Opin Oncol 2018; 30: 107-112
  • 38 Kollar A, Jones RL, Stacchiotti S. et al. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol 2017; 56: 88-92
  • 39 Florou V, Rosenberg AE, Wieder E. et al. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J Immunother Cancer 2019; 7: 213
  • 40 Honda Y, Otsuka A, Ono S. et al. Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma. Oncoimmunology 2017; 6: e1253657
  • 41 Fury MG, Antonescu CR, Van Zee KJ. et al. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 2005; 11: 241-247
  • 42 Albores-Saavedra J, Schwartz AM, Henson DE. et al. Cutaneous angiosarcoma. Analysis of 434 cases from the Surveillance, Epidemiology, and End Results Program, 1973–2007. Ann Diagn Pathol 2011; 15: 93-97
  • 43 Moosazadeh M, Shafaroudi AM, Gorji NE. et al. Prevalence of oral lesions in patients with AIDS: a systematic review and meta-analysis. Evid Based Dent 2021; DOI: 10.1038/s41432-021-0209-8.
  • 44 Ramaswami R, Lurain K, Yarchoan R. Oncologic Treatment of HIV-Associated Kaposi Sarcoma 40 Years on. J Clin Oncol 2022; 40: 294-306
  • 45 Regnier-Rosencher E, Guillot B, Dupin N. Treatments for classic Kaposi sarcoma: a systematic review of the literature. J Am Acad Dermatol 2013; 68: 313-331
  • 46 Ferioli M, Galuppi A, Buwenge M. et al. Electrochemotherapy in Kaposi sarcoma: A systematic review. Mol Clin Oncol 2021; 14: 64
  • 47 Oyucu Orhan S, Bilgehan Sahin A, Cubukcu E. et al. Efficacy of chemotherapeutics in classic and non-classic Kaposi sarcoma: A single-center retrospective real-world data. Bosn J Basic Med Sci 2021; 21: 746-751
  • 48 Colafigli M, Ciccullo A, Borghetti A. et al. Impact of Antiretroviral Therapy on the Risk of Recurrence in HIV-1 Infected Patients with Kaposi Sarcoma: A Multicenter Cohort Experience. J Clin Med 2019; 8: 2062
  • 49 Piselli P, Taborelli M, Cimaglia C. et al. Decreased incidence of Kaposi sarcoma after kidney transplant in Italy and role of mTOR-inhibitors: 1997–2016. Int J Cancer 2019; 145: 597-598